SCRIPT: Sickle Cell Risk in Pregnancy Tool
Enrolling by invitation
Conditions studied: Sickle Cell Disease, Pregnancy, High Risk, Pregnancy Complications
In brief
Sickle Cell Disease (SCD), common in persons of Black ancestry, affects the shape of hemoglobin, the oxygen-carrying part of red blood cells (RBC). It is characterized by many complications, the most dreaded of which are related to pregnancy - affecting both the mother and unborn child. Compared to those without SCD, people with SCD have more adverse pregnancy outcomes (APO): 6x maternal mortality, 2x preeclampsia \& preterm birth, 4x risk of having a baby not growing well in the womb \& stillbirth. There is also greater need for access to care (7x higher hospitalization often multiple times lasting days to months). Yet up to 30% of SCD pregnancies are uncomplicated. Treatments in pregnancy are limited and carry risks. A method to distinguish pregnancies at high-risk of APO that may benefit from these potentially risky treatments, from those likely to be uncomplicated, is urgently needed. To meet this need, the investigators developed a calculator to estimate pregnancy complication risk, using single-centre data. Its accuracy and precision will now be evaluated with international information from several centers by testing the calculator, and adjusting it as needed, using already available pregnancy-data from study centres in several countries. Those age \>16 years, who have a confirmed SCD genotype, pregnancy with one baby, and pregnancy care and birth at a participating study centre will be included. Pregnancy care for the participants will be up to their doctors, with no changes based on the study. SCRIPT - the new tool - will guide future care by predicting who may benefit from specific treatments, reducing harm to low-risk individuals \& will allow selection of high-risk patients for a future trials to determine whether currently available and novel treatments in well-selected patients can improve APO sufficiently to balance treatment-related harms.
Key facts
- Study ID
- NCT06529042
- Run by
- Mount Sinai Hospital, Canada
- People needed
- 1000
- Starts
- 2024-09-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2024-11-27
Who can join
Age: 16 and older, up to 60. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Age >16 years
- HbSS, HbSC, HbS/β0-thalassemia, HbS/β+-thalassemia confirmed on Hb electrophoresis, high performance liquid chromatography, capillary electrophoresis, or genetic testing
- Records of pregnancy care and birth at a participating centre
- Pregnancy continuing to at least 16+0 weeks' gestation (41,42)
You may not qualify if…
- Inability to confirm SCD genotype
- Incomplete medical records.
Where it is running
- Johns Hopkins University — Baltimore, Maryland, United States
- Providence Health Care — Vancouver, British Columbia, Canada
- Centre hospitalier de l'Université de Montréal — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.